Department of Radiology, UT Southwestern Medical Center, Dallas, TX, USA.
Transl Oncol. 2011 Dec;4(6):355-64. doi: 10.1593/tlo.11178. Epub 2011 Dec 1.
Phosphatidylserine (PS) is normally intracellular but becomes exposed on the luminal surface of vascular endothelial cells in tumors. It also becomes exposed on tumors cells responding to therapy. In the present study, we optically imaged exposed PS in vivo using PGN635, a novel monoclonal antibody that binds PS. The F(ab')(2) fragment of PGN635 was labeled with the near-infrared (NIR) dye, IRDye800CW. In vivo dynamic NIR imaging was performed after injection of 800CW-PGN635 into mice bearing radiation-treated or untreated U87 glioma xenografts growing subcutaneously or orthotopically. NIR optical imaging revealed a clear tumor contrast in nonirradiated subcutaneous U87 gliomas after injection of 800CW-PGN635. The tumor contrast was visible as early as 4 hours later and was maximal 24 hours later (tumor-to-normal tissue ratio [TNR] = 2.8 ± 0.7). Irradiation enhanced the tumor contrast at 24 hours (TNR = 4.0 ± 0.3). Similar results were observed for orthotopic gliomas. Localization of 800CW-PGN635 to tumors was antigen specific because 800CW-Aurexis, a control probe of irrelevant specificity, did not localize to the tumors, and preadministration of unlabeled PGN635 blocked the uptake of 800CW-PGN635. Fluorescence microscopy confirmed that 800CW-PGN635 was binding to PS-positive vascular endothelial cells in nonirradiated gliomas. Irradiation of the gliomas increased PS exposure on both tumor vascular endothelial cells and tumor cells and gave rise to an increase in tumor contrast with 800CW-PGN635 that was predictive of the reduction in tumor growth. 800CW-PGN635 may be a useful new imaging probe for detection of exposed PS in tumors responding to therapy.
磷脂酰丝氨酸(PS)通常在细胞内,但在肿瘤的血管内皮细胞的腔表面变得暴露。它也在对治疗有反应的肿瘤细胞中变得暴露。在本研究中,我们使用结合 PS 的新型单克隆抗体 PGN635 对体内暴露的 PS 进行光学成像。PGN635 的 F(ab')(2)片段用近红外(NIR)染料 IRDye800CW 标记。在皮下或原位接种经辐射处理或未经处理的 U87 神经胶质瘤异种移植物的小鼠中注射 800CW-PGN635 后,进行体内动态 NIR 成像。在注射 800CW-PGN635 后,非照射的皮下 U87 神经胶质瘤中可以清楚地看到肿瘤对比。肿瘤对比早在 4 小时后即可看到,24 小时后最大(肿瘤与正常组织比 [TNR] = 2.8 ± 0.7)。照射在 24 小时增强了肿瘤对比(TNR = 4.0 ± 0.3)。对于原位神经胶质瘤也观察到了类似的结果。800CW-PGN635 定位于肿瘤是抗原特异性的,因为与无关特异性的对照探针 800CW-Aurexis 未定位于肿瘤,并且未标记的 PGN635 的预先给药阻止了 800CW-PGN635 的摄取。荧光显微镜证实,800CW-PGN635 与未照射的神经胶质瘤中 PS 阳性的血管内皮细胞结合。对神经胶质瘤的照射增加了肿瘤血管内皮细胞和肿瘤细胞上 PS 的暴露,并导致 800CW-PGN635 的肿瘤对比增加,这与肿瘤生长减少有关。800CW-PGN635 可能是检测对治疗有反应的肿瘤中暴露 PS 的一种有用的新型成像探针。